Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Psychopharmacologic Drugs Advisory Committee

Executive Summary

Will consider Janssen's Resperidal (risperidone) in the treatment of psychotic disorders at its April 29 session. On April 30, the committee will discuss NDA for Wyeth-Ayerst's Effexor (venlafaxine) for treatment of depression. The meeting begins at 8 a.m. on both days in conference rooms D & E in FDA's Parklawn building.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel